Kyverna Therapeutics (KYTX) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Kyverna Therapeutics in August 2026.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Kyverna Therapeutics' stock with a target price of $32.5, indicating significant growth potential.
Financial Health
Kyverna Therapeutics is showing strong financial performance with healthy cash flow and solid book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
